Home » Stocks » Jounce Therapeutics

Jounce Therapeutics, Inc. (JNCE)

Stock Price: $9.55 USD -0.29 (-2.95%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 326.75M
Revenue (ttm) 119.45M
Net Income (ttm) 21.78M
Shares Out 34.21M
EPS (ttm) 0.63
PE Ratio 15.16
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $9.55
Previous Close $9.84
Change ($) -0.29
Change (%) -2.95%
Day's Open 9.83
Day's Range 9.47 - 9.89
Day's Volume 305,531
52-Week Range 2.85 - 11.72

More Stats

Market Cap 326.75M
Enterprise Value 217.92M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 34.21M
Float 16.59M
EPS (basic) 0.70
EPS (diluted) 0.63
FCF / Share -0.91
Dividend n/a
Dividend Yield n/a
Earnings Yield 6.60%
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.59M
Short Ratio 0.51
Short % of Float 9.56%
Beta 1.69
PE Ratio 15.16
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 2.74
PB Ratio 2.67
Revenue 119.45M
Operating Income 18.88M
Net Income 21.78M
Free Cash Flow -31.10M
Net Cash 108.83M
Net Cash / Share 3.18
Gross Margin 102.14%
Operating Margin 15.81%
Profit Margin 18.20%
FCF Margin -26.04%
ROA 6.75%
ROE 20.05%
ROIC 16.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 3
Overweight 1
Hold 2
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

$14.30*
(49.74% upside)
Low
5.50
Current: $9.55
High
28.00
Target: 14.30
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue14865.2071.6437.20--
Revenue Growth126.79%-8.99%92.61%---
Gross Profit14865.2071.6437.20--
Operating Income52.82-31.29-19.22-14.47-30.40-16.21
Net Income56.82-27.38-16.44-13.70-28.53-10.52
Shares Outstanding33.0832.5730.062.101.621.18
Earnings Per Share1.66-0.84-0.57-11.00-23.13-10.93
Operating Cash Flow-30.13-63.61-90.99180-25.74-14.91
Capital Expenditures-0.99-1.36-15.11-2.22-2.20-0.70
Free Cash Flow-31.11-64.97-106177-27.94-15.61
Cash & Equivalents16919023614945.1645.16
Total Debt19.79-----
Net Cash / Debt14919023614945.1645.16
Assets20621429727152.9852.98
Liabilities31.291101301998.128.12
Book Value175104167-69.09-58.76-58.76
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Jounce Therapeutics, Inc.
Country United States
Employees 130
CEO Richard Murray

Stock Information

Ticker Symbol JNCE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: JNCE
IPO Date January 27, 2017

Description

Jounce Therapeutics, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase II clinical trial for the treatment of PD-1/PD-L1 inhibitor patients with non-small cell lung cancer and urothelial cancer. It is also developing JTX-4014, a clinical-stage anti-PD-1 antibody for combination therapy; and JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment that is in the IND-enabling phase. The company's product candidate includes JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.